Enjeux et écueils des thérapies ciblées orales en pratique clinique quotidienne : 5e journée de pharmacologie des anti-tumoraux

Zaibet, Sonia; Vauchier, Charles; Khoudour, Nihel; Dugage, Matthieu Roulleaux; Korb-Savoldelli, Virginie; Alexandre, Jérôme; Blanchet, Benoı̂t; Goldwasser, François; Thomas-Schoemann, Audrey; Bellesœur, Audrey

doi:10.1016/j.bulcan.2018.08.005

Cited by 3 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Innovative drugs can be made early available, sometimes on the basis of results of phase II trials or of interim analyses of phase III trials; in that case, real‐life assessment is crucial to ensure the safety profile and effectiveness [4]. The increasing number of therapeutic options and the fast changes in recommendations point out challenges for prescribers, to ensure a safe and individualized prescription [5]. The economic perspective is also crucial because treatment costs can be high and undermine the sustainability of healthcare systems, especially those providing universal coverage [6,7].…”

Section: Introductionmentioning

confidence: 99%

Overview of French databases available for studying anticancer drugs in real‐life setting

Casarotto

Noïze

Gouverneur

et al. 2020

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Considering their novelty and cost, post‐marketing evaluation is highly relevant for new anticancer drugs. Identify and characterize available and potentially useful databases for post‐marketing evaluation of these specific drugs is necessary. A review was conducted to identify available and accessible databases to study the post‐marketing evaluation of drugs in real‐life care setting. Databases identified have been classified into medico‐administrative databases, medical record databases, and databases resulting from ad hoc collections. Taking as examples databases available in France, each type was described as well as its strengths and limits for a potential use in the oncology field. Record linkage of medico‐administrative databases could cover almost the whole population and is now used to evaluate anticancer drugs (e.g., Système National des Données de Santé). Large medical record databases are still lacking, but efforts are currently made to give access to hospital data warehouses for research purposes. Finally, databases resulting from ad hoc collections are also available for some cancer localizations and allow to obtain highly valuable clinical and biological data. A range of important and valuable databases exist but, individually, none is enough to answer to all questions from health authorities, healthcare professionals, and patients. In order to obtain a complete overview on utilization, associated health outcomes and costs of these drugs, it seems necessary to better interlink available databases.

show abstract

Section: Introductionmentioning

confidence: 99%

Overview of French databases available for studying anticancer drugs in real‐life setting

Casarotto

Noïze

Gouverneur

et al. 2020

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations

Ferrer

Fanciullino

Milano

et al. 2020

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

The current trend to personalize anticancer therapies mostly relies on selecting the best drug or combination of drugs to achieve optimal efficacy in patients. In addition to the comprehensive genetic and molecular knowledge of each tumor before choosing the drugs to be given, there is probably much room left for improvement by further personalizing the very modes by which the drugs are given, once they have been carefully selected. In particular, shifting from standard dosing to tailored dosing should help in maintaining drug exposure levels in the right therapeutic window, thus ensuring that the efficacy/toxicity balance is optimal. This paper covers the current knowledge regarding pharmacokinetic/pharmacodynamic relationships of anticancer agents, from decades‐old cytotoxics to the latest immune checkpoint inhibitors, the most frequent sources for long‐neglected interpatient variability impacting on drug exposure levels, and what could be done to achieve real personalized medicine in oncology such as implementing therapeutic drug monitoring with adaptive dosing strategies or using model‐driven modalities for personalized dosing and scheduling.

show abstract

Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II

Ferrer,

Tetu,

Dousset

et al. 2024

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Enjeux et écueils des thérapies ciblées orales en pratique clinique quotidienne : 5e journée de pharmacologie des anti-tumoraux

Cited by 3 publications

References 41 publications

Overview of French databases available for studying anticancer drugs in real‐life setting

Overview of French databases available for studying anticancer drugs in real‐life setting

Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations

Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II

Contact Info

Product

Resources

About